{
  "ticker": "VIR",
  "company_name": "VIR",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05780281",
      "title": "VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "COVID-19",
      "start_date": "2020-12-16",
      "completion_date": "2022-10-04",
      "enrollment": 0,
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
    },
    {
      "nct_id": "NCT06070051",
      "title": "Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Chronic Hepatitis B",
      "start_date": "2023-09-26",
      "completion_date": "2026-03-31",
      "enrollment": 0,
      "sponsor": "Virion Therapeutics"
    },
    {
      "nct_id": "NCT06960395",
      "title": "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR",
      "start_date": "2025-07-22",
      "completion_date": "2029-08",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT05461170",
      "title": "SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Hepatitis D, Chronic",
      "start_date": "2022-09-17",
      "completion_date": "2029-08",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT05970289",
      "title": "Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFN\u03b1 Combination Therapy in Chronic HBV Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Chronic Hepatitis B Virus Infection",
      "start_date": "2023-08-22",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "Brii Biosciences Limited"
    },
    {
      "nct_id": "NCT05356741",
      "title": "To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Locally Advanced or Metastatic HER2-Expressing Cancers",
      "start_date": "2022-04-13",
      "completion_date": "2027-08-16",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT04856085",
      "title": "Study of VIR-2218, VIR-3434, and/or PEG-IFN\u03b1 in Subjects With Chronic Hepatitis B Virus Infection",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Hepatitis B, Chronic",
      "start_date": "2021-07-11",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    },
    {
      "nct_id": "NCT06491563",
      "title": "Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFN\u03b1 Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "For Treatment of Chronic Hepatitis B Virus Infection",
      "start_date": "2024-08-06",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Brii Biosciences Limited"
    },
    {
      "nct_id": "NCT05135650",
      "title": "Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm",
      "start_date": "2022-01-25",
      "completion_date": "2023-01-10",
      "enrollment": 0,
      "sponsor": "Fred Hutchinson Cancer Center"
    },
    {
      "nct_id": "NCT07128550",
      "title": "A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Viral Hepatitis",
      "start_date": "2025-07-30",
      "completion_date": "2031-07",
      "enrollment": 0,
      "sponsor": "Vir Biotechnology, Inc."
    }
  ],
  "summary": {
    "total_trials": 35,
    "by_phase": {
      "PHASE3": 5,
      "PHASE1": 11,
      "PHASE2": 13,
      "PHASE1, PHASE2": 3,
      "PHASE2, PHASE3": 1,
      "": 2
    },
    "by_status": {
      "COMPLETED": 17,
      "ACTIVE_NOT_RECRUITING": 6,
      "RECRUITING": 6,
      "TERMINATED": 5,
      "NO_LONGER_AVAILABLE": 1
    },
    "active_trials": 12,
    "completed_trials": 17,
    "conditions": [
      "COVID-19",
      "COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm",
      "Chronic Hepatitis B",
      "Chronic Hepatitis B Virus Infection",
      "Covid19",
      "Covid19, SARS-CoV Infection",
      "For Treatment of Chronic Hepatitis B Virus Infection",
      "HIV I Infection",
      "Hepatic Impairment, Cirrhosis",
      "Hepatitis B, Chronic",
      "Hepatitis D, Chronic",
      "Hormone-refractory Prostate Cancer",
      "Influenza A",
      "Locally Advanced or Metastatic HER2-Expressing Cancers",
      "Renal Impairment",
      "Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR",
      "Viral Hepatitis"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T10:02:47.189954",
    "search_query": "VIR",
    "url": "https://clinicaltrials.gov/search?term=VIR"
  }
}